Tag Archives: undefined

A New Biotech ETF Targets Companies In Late Stage Clinical Trials

Summary ALPS Medical Breakthroughs ETF targets biotech and pharmaceutical companies with drugs in Stage II or Stage III clinical trials. This ETF looks for small cap and mid cap companies with greater liquidity and enough cash on hand to survive for at least two years. The management fee for this product is very reasonable compared to other similar products in the biotech area. The boom or bust nature of many of these companies makes it appropriate for only a smaller portion of your portfolio. ETF providers seem eager to take advantage of the popularity of biotechs recently. The biotech sector as measured by the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB ) was up 34% in 2014 and has seen its assets more than double in the past 18 months. In addition, five new biotech ETFs have been launched since the end of 2014 and four of them are targeting unique niches within the biotech universe. I covered one of those ETFs – the BioShares Biotechnology Clinical Trials ETF (NASDAQ: BBC ) – recently and now another specialty biotech ETF has hit the market. The ALPS Medical Breakthroughs ETF (NYSEARCA: SBIO ) launched on December 31, 2014 and is targeting biotech and pharmaceutical companies that have one or more drugs currently in later stage clinical trials. According to the fund’s fact sheet , the company needs to meet the following criteria in order to be considered for inclusion in the ETF: U.S. listed biotech or pharmaceutical firm with 1 or more drugs in Phase II or Phase III FDA clinical trials Enough cash for 24 months at current burn rate Maximum weighting of 4.5% of assets at rebalance A market cap between $200 million and $5 billion Average daily volume > $1 million The fund mandate appears to be logical. Many of the big biotech firms have been having trouble getting new drugs in the pipeline so the focus here is to look instead at the smaller and midsize companies that have promising drugs that are potentially nearing approval. The benefit is two-fold. The approval of a drug that becomes successful in the market could become a huge cash cow for the company and for smaller companies like these could literally alter their landscape. The companies that have a newly approved drug could also end up being the target of a larger firm looking to add to their own channels. With an expense ratio of 0.50%, the management fee for this ETF is quite reasonable. Biotech is one of the sectors that most investors would benefit from putting the professionals in charge as researching and choosing investments individually among the drug companies can be quite cumbersome and costly if not done properly. It probably goes without saying though that the risk involved in these companies can be significant. Since we’re dealing with drugs that are in clinical trial but not yet approved, there’s a bit of a boom or bust proposition here as there’s no guarantee that any of these in-trial drugs will get approved. A drug that gets rejected represents months of work and millions in cost that will see no return on investment and therefore the volatility with these companies can be very high. Investors should only allocate a small portion of their portfolios to a product like this. Conclusion The idea of striking while the iron is hot is nothing new so it’s not surprising to see several new biotech ETFs popping up. This ETF’s focus is particularly intriguing as targeting biotech companies that are making significant investment in and progress towards developing new drugs can be quite lucrative to investors. The management style seems well thought out as well. The 24 months of cash requirement helps ensure that these companies will be around for a while and have the time and resources to develop their products. Looking for companies with a higher trading volume allows investors to buy and sell shares without that high bid-ask spreads that could make investment in these companies unnecessarily costly. Given the target niche of the biotech sector, the company selection philosophy and the reasonable cost, this ETF should be a consideration for investors looking for exposure to biotechs. Now that you’ve read this, are you Bullish or Bearish on ? Bullish Bearish Sentiment on ( ) Thanks for sharing your thoughts. Why are you ? Submit & View Results Skip to results » Share this article with a colleague

EWRS Brings Small Cap Exposure And Low Correlations, But Poor Liquidity Hurts It

Summary I’m taking a look at EWRS as a candidate for inclusion in my ETF portfolio. The low correlation is very attractive, but isn’t reliable because of poor liquidity. I’ll have to do further investigation to see if it is real. I’ll keep it on my list for potential exposure to small caps. The internal diversification of holdings within the ETF is excellent and an equal weighting scheme sounds very attractive relative to market cap strategies. I’m not assessing any tax impacts. Investors should check their own situation for tax exposure. How to read this article : If you’re new to my ETF articles, just keep reading. If you have read this intro to my ETF articles before, skip down to the line of asterisks. This section introduces my methodology. By describing my method initially, investors can rapidly process each ETF analysis to gather the most relevant information in a matter of minutes. My goal is to provide investors with immediate access to the data that I feel is most useful in making an investment decision. Some of the information I provide is readily available elsewhere, and some requires running significant analysis that, to my knowledge, is not available for free anywhere else on the internet. My conclusions are also not available anywhere else. What I believe investors should know My analysis relies heavily on Modern Portfolio Theory. Therefore, I will be focused on the statistical implications of including a fund in a portfolio. Since the potential combinations within a portfolio are practically infinite, I begin by eliminating ETFs that appear to be weak relative to the other options. It would be ideal to be able to run simulations across literally billions of combinations, but it is completely impractical. To find ETFs that are worth further consideration I start with statistical analysis. Rather than put readers to sleep, I’ll present the data in charts that only take seconds to process. I include an ANOVA table for readers that want the deeper statistical analysis, but readers that are not able to read the ANOVA table will still be able to understand my entire analysis. I believe there are two methods for investing. Either you should know more than the other people performing analysis so you can make better decisions, or use extensive diversification and math to outperform most investors. Under CAPM (Capital Asset Pricing Model), it is assumed every investor would hold the same optimal portfolio and combine it with the risk free asset to reach their preferred spot on the risk and return curve. Do you know anyone that is holding the exact same portfolio you are? I don’t know of anyone else with exactly my exposure, though I do believe there are some investors that are holding nothing but SPY. In general, I believe most investors hold a portfolio that has dramatically more risk than required to reach their expected (under economics, disregarding their personal expectations) level of returns. In my opinion, every rational investor should be seeking the optimal combination of risk and reward. For any given level of expected reward, there is no economically justifiable reason to take on more risk than is required. However, risk and return can be difficult to explain. Defining “Risk” I believe the best ways to define risk come from statistics. I want to know the standard deviation of the returns on a portfolio. Those returns could be measured daily, weekly, monthly, or annually. Due to limited sample sizes because some of the ETFs are relatively new, I usually begin by using the daily standard deviation. If the ETF performs well enough to stay on my list, the next levels of analysis will become more complex. Ultimately, we probably shouldn’t be concerned about volatility in our portfolio value if the value always bounced back the following day. However, I believe that the vast majority of the time the movement today tells us nothing about the movement tomorrow. While returns don’t dictate future returns, volatility over the previous couple years is a good indicator of volatility in the future unless there is a fundamental change in the market. Defining “Returns” I see return as the increase over time in the value known as “dividend adjusted close”. This value is provided by Yahoo. I won’t focus much on historical returns because I think they are largely useless. I care about the volatility of the returns, but not the actual returns. Predicting returns for a future period by looking at the previous period is akin to placing a poker bet based on the cards you held in the previous round. Defining “Risk Adjusted Returns” Based on my definitions of risk and return, my goal is to maximize returns relative to the amount of risk I experienced. It is easiest to explain with an example: Assume the risk free rate is 2%. Assume SPY is the default portfolio. Then the risk level on SPY is equal to one “unit” of risk. If SPY returns 6%, then the return was 4% for one unit of risk. If a portfolio has 50% of the risk level on SPY and returns 4%, then the portfolios generated 2% in returns for half of one unit of risk. Those two portfolios would be equal in providing risk adjusted returns. Most investors are fueled by greed and focused very heavily on generating returns without sufficient respect for the level of risk. I don’t want to compete directly in that game, so I focus on reducing the risk. If I can eliminate a substantial portion of the risk, then my returns on a risk adjusted basis should be substantially better. Belief about yields I believe a portfolio with a stronger yield is superior to one with a weaker yield if the expected total return and risk is the same. I like strong yields on portfolios because it protects investors from human error. One of the greatest risks to an otherwise intelligent investor is being caught up in the mood of the market and selling low or buying high. When an investor has to manually manage their portfolio, they are putting themselves in the dangerous situation of responding to sensationalistic stories. I believe this is especially true for retiring investors that need money to live on. By having a strong yield on the portfolio it is possible for investors to live off the income as needed without selling any security. This makes it much easier to stick to an intelligently designed plan rather than allowing emotions to dictate poor choices. In the recent crash, investors that sold at the bottom suffered dramatic losses and missed out on substantial gains. Investors that were simply taking the yield on their portfolio were just fine. Investors with automatic rebalancing and an intelligent asset allocation plan were in place to make some attractive gains. Personal situation I have a few retirement accounts already, but I decided to open a new solo 401K so I could put more of my earnings into tax advantaged accounts. After some research, I selected Charles Schwab as my brokerage on the recommendation of another analyst. Under the Schwab plan “ETF OneSource” I am able to trade qualifying ETFs with no commissions. I want to rebalance my portfolio frequently, so I have a strong preference for ETFs that qualify for this plan. Schwab is not providing me with any compensation in any manner for my articles. I have absolutely no other relationship with the brokerage firm. Because this is a new retirement account, I will probably begin with a balance between $9,000 and $11,000. I intend to invest very heavily in ETFs. My other accounts are with different brokerages and invested in different funds. Views on expense ratios Some analysts are heavily opposed to focusing on expense ratios. I don’t think investors should make decisions simply on the expense ratio, but the economic research I have covered supports the premise that overall higher expense ratios within a given category do not result in higher returns and may correlate to lower returns. The required level of statistical proof is fairly significant to determine if the higher ratios are actually causing lower returns. I believe the underlying assets, and thus Net Asset Value, should drive the price of the ETF. However, attempting to predict the price movements of every stock within an ETF would be a very difficult and time consuming job. By the time we want to compare several ETFs, one full time analyst would be unable to adequately cover every company. On the other hand, the expense ratio is the only thing I believe investors can truly be certain of prior to buying the ETF. Taxes I am not a CPA or CFP. I will not be assessing tax impacts. Investors needing help with tax considerations should consult a qualified professional that can assist them with their individual situation. The rest of this article By disclosing my views and process at the top of the article, I will be able to rapidly present data, analysis, and my opinion without having to explain the rationale behind how I reached each decision. The rest of the report begins below: ******** (NYSEARCA: EWRS ): Guggenheim Russell 2000 Equal Weight ETF Tracking Index: Guggenheim Russell 2000 Equal Weight Index Allocation of Assets: At least 80% in assets included in the index Morningstar Category: Small Blend Time period starts: April 2012 Time period ends: December 2014 Portfolio Std. Deviation Chart: (click to enlarge) (click to enlarge) Correlation: 73.45% Returns over the sample period: (click to enlarge) Liquidity (Average shares/day over last 10): 4,379 Days with no change in dividend adjusted close: 42 Days with no change in dividend adjusted close for SPY: Yield: 1.01% Distribution Yield Expense Ratio: .45% Discount or Premium to NAV: .10% premium Holdings: (click to enlarge) Further Consideration: I’ll keep EWRS in my potential list for now Conclusion: There are quite a few things I like about EWRS, but also a few problems will merit deeper analysis. The good things are the low correlation and the equal weighting of the index was very impressive diversification within the ETF. The largest hold at reached a market weight of .30%. That is incredible diversification within the ETF. Even if the ETF is aiming for an exact equal weighting, they can’t reasonably be rebalancing constantly so there should be some deviations. The bad news is that the liquidity is absolutely terrible and the terrible liquidity may have been a driving factor in the 42 days with no change in dividend adjusted closes. This is one of the ETFs where poor liquidity could be reducing the reliability of the statistics. If the correlation is significantly higher than it appears but is being understated because of poor liquidity, it would make the ETF significantly less attractive. The combination of poor liquidity and low yield makes the ETF substantially less attractive for investors that are seeking income or needing liquidity. While I’m willing to cope with those problems if the correlation turns out to be accurate, I still don’t like the expense ratio much. Given that the portfolio is to be equally weighted and has very small exposure to each individual stock, I would be willing to accept the expenses if I was using the portfolio as a small part of my portfolio. This may be a decent option for getting some small cap exposure into my portfolio. If I pick EWRS, I’d only plan on using it for 5% to 10% of the portfolio. If poor liquidity is a major issue when the markets are open, I would consider keeping an eye on NAV and using a (one day) limit order to try to buy up a piece for a 1 to 2% discount to NAV. I would consider the ETF fairly attractive if it could be purchased at that kind of discount to NAV.

How My Value Investing Strategies Performed In 2014

Summary 2014 was a tough year in the markets but there was a strategy that outperformed the market with a gain of 24.5%. Quarterly breakdown of results for the 15 different value investing strategies I follow are provided. A detailed look at the stock portfolio that outperformed in 2014. In ancient Roman mythology, there is a god with two faces. His name is Janus, and with two faces, he looks in both directions representing the past and future. It’s also where the word January came from. Although January 2015 is fully under way, it’s appropriate because we are still at a stage of looking back at 2014, while also looking at what lies ahead in 2015. Now one of the very last tasks of the year (or first of the year) that I do is to go through all the performances of the value stock screeners and see what worked and what didn’t. I don’t bother with gathering results for all different asset classes and sectors because there are plenty of people who are better than me at this. It’s easier to leverage the work of others and to put my value strategies into context. Here’s the best chart I came across showing the performance of the major asset classes. (click to enlarge) Yearly Asset Performance Chart (Credit: awealthofcommonsense.com ) Because my focus has always been on value stocks, the stocks shown on the value screens all fall into the large, mid and small cap boxes above. But most of those stocks should be categorized into the small cap group which managed 3% on the year. So in the grand scheme of things, no matter how good the strategy or quality of the company was, small caps had a rough 2014. It goes to show how difficult it is to beat the market. The market isn’t going to award you easily just because the company has strong fundamentals. What works one year, may not the next and it’s a test of conviction and temperament to see it through. That’s why having a clear process to buy and sell stocks and to focus on creating long term wealth is important over short-term gains. Sure it feels good when you beat the market, but that’s something you can leave to fund managers who are judged based on their quarterly or yearly results. You and I have the luxury of looking 5 or 10 years down the road and comparing performance then. A few bad years after having achieved 200% vs. the market’s 100% over a 10-year period isn’t important. The end goal is to outperform the market over the long run because you aren’t trying to invest for a few months and then call it quits. With that in mind, here are the final 2014 results for each of the Value Screeners . 2014 Value Screener Results Before getting into the results, a very common question that I receive daily is whether the OSV Analyzer will screen for stocks and tell people what to buy and sell. I want to start by clearing up that these strategies are not created with the OSV Analyzer. The OSV Analyzer is a deep fundamental analysis and valuation tool. A tool to drill down deeply into a single company quickly instead of just scratching the surface and looking at basic stats. Screening will come in the future. With that out of the way, here are the results. (click to enlarge) Out of 15 value strategies, only 4 managed to outperform the market at the end of the year. The outperforming strategies ( Altman , Graham , Piotroski ) were the ones that contained a lot of mid and large caps. With the Altman Z value screen leading the pack this year, here’s a look at the 20 stocks that made up the list from the beginning of the year and how each performed. (click to enlarge) There are stocks that I definitely wouldn’t purchase, but that’s the beauty of mechanical investing. It’s simplified down to how well you create a strategy and stick with it. This reduces many of the variables that go into individual stock picking. However, I still find it difficult to give up total control of my portfolio. I prefer to further filter the list with my analyzer because screeners still make mistakes. Manual analysis is also required because there are things like off balance sheet items screens can’t recognize and qualitative events that can’t be simulated. But if this was something that I want to follow with real money, I’ll want to create a new account with at least $20k instead of using money from my existing portfolio. Not the Time to Invest in US Net Nets One sure thing about 2014 was that it wasn’t a good year for net nets. It’s especially clear looking at the Net Net performance. Since the results are all US listed stocks, the horrible performance isn’t surprising. When markets are hot, stay away from employing a pure USA net net investing strategy. You need to expand to international net nets if you want to stick with Graham’s net nets. But right now, there aren’t many US net nets that you should be investing in. The ones you see floating around the stock market have serious issues. The official screeners identified around 5-6 stocks at the start of the year and the minimum that I test with is always 20 stocks. For any mechanical strategy where you have to trust the theory and the system, holding 5-6 stocks is going to get you killed. The full 20 stocks are required for the portfolio to be diversified enough for each strategy to work over the long run. As I showed previously , when the number of net nets increase, it’s definitely a sign that the market is getting cheaper and that’s the time to be loading up on good net nets. Just not now. In the next post, I’ll be listing the official stocks for each screen that will be tracked for 2015. It features a list of 225 value stocks you can download and to get ideas.